23 research outputs found
Experimental and Therapeutic Opportunities for Stem Cells in Multiple Sclerosis
Multiple Sclerosis (MS) is an inflammatory demyelinating neurodegenerative disorder of the brain and spinal cord that causes significant disability in young adults. Although the precise aetiopathogenesis of MS remains unresolved, its pathological hallmarks include inflammation, demyelination, axonal injury (acute and chronic), astrogliosis and variable remyelination. Despite major recent advances in therapeutics for the early stage of the disease there are currently no disease modifying treatments for the progressive stage of disease, whose pathological substrate is axonal degeneration. This represents the great and unmet clinical need in MS. Against this background, human stem cells offer promise both to improve understanding of disease mechanism(s) through in-vitro modeling as well as potentially direct use to supplement and promote remyelination, an endogenous reparative process where entire myelin sheaths are restored to demyelinated axons. Conceptually, stem cells can act directly to myelinate axons or indirectly through different mechanisms to promote endogenous repair; importantly these two mechanisms of action are not mutually exclusive. We propose that discovery of novel methods to invoke or enhance remyelination in MS may be the most effective therapeutic strategy to limit axonal damage and instigate restoration of structure and function in this debilitating condition. Human stem cell derived neurons and glia, including patient specific cells derived through reprogramming, provide an unprecedented experimental system to model MS “in a dish” as well as enable high-throughput drug discovery. Finally, we speculate upon the potential role for stem cell based therapies in MS
Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study.
BACKGROUND AND AIMS: Despite advances in our knowledge of effective services for people who use drugs over the last decades globally, coverage remains poor in most countries, while quality is often unknown. This paper aims to discuss the historical development of successful epidemiological indicators and to present a framework for extending them with additional indicators of coverage and quality of harm reduction services, for monitoring and evaluation at international, national or subnational levels. The ultimate aim is to improve these services in order to reduce health and social problems among people who use drugs, such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection, crime and legal problems, overdose (death) and other morbidity and mortality. METHODS AND RESULTS: The framework was developed collaboratively using consensus methods involving nominal group meetings, review of existing quality standards, repeated email commenting rounds and qualitative analysis of opinions/experiences from a broad range of professionals/experts, including members of civil society and organisations representing people who use drugs. Twelve priority candidate indicators are proposed for opioid agonist therapy (OAT), needle and syringe programmes (NSP) and generic cross-cutting aspects of harm reduction (and potentially other drug) services. Under the specific OAT indicators, priority indicators included 'coverage', 'waiting list time', 'dosage' and 'availability in prisons'. For the specific NSP indicators, the priority indicators included 'coverage', 'number of needles/syringes distributed/collected', 'provision of other drug use paraphernalia' and 'availability in prisons'. Among the generic or cross-cutting indicators the priority indicators were 'infectious diseases counselling and care', 'take away naloxone', 'information on safe use/sex' and 'condoms'. We discuss conditions for the successful development of the suggested indicators and constraints (e.g. funding, ideology). We propose conducting a pilot study to test the feasibility and applicability of the proposed indicators before their scaling up and routine implementation, to evaluate their effectiveness in comparing service coverage and quality across countries. CONCLUSIONS: The establishment of an improved set of validated and internationally agreed upon best practice indicators for monitoring harm reduction service will provide a structural basis for public health and epidemiological studies and support evidence and human rights-based health policies, services and interventions
Semi-Lagrangian advection scheme with controlled damping: An alternative to nonlinear horizontal diffusion in a numerical weather prediction model
International audienceThis paper proposes a nonlinear horizontal diffusion scheme for models using semi-Lagrangian formulations. The scheme is made flow dependent and not entirely linked to the model levels. As an extension, the implementation of the scheme to the model Aladin is given. The damping abilities of interpolation are used for the diffusion filtering. The aim is to provide a horizontal diffusion scheme of similar stability and computational efficiency as the existing linear spectral diffusion scheme in Aladin. Preserving such qualities, the new scheme brings beneficial new skills to the model. The differences between the performances of the two diffusion schemes are examined and discussed. Finally, some interesting case-studies simulated with both horizontal diffusion schemes are presented.Copyright © 2008 Royal Meteorological Societ
Co2Sensing With A 1.432 Μm Nd:Yalo3Laser
A smoothly tunable 1.432 μm Nd:YAlO3 laser was assembled for potential remote sensing of atmospheric CO2 at high altitudes. Continuous laser tuning from 6982.8 to 6984.6 cm-1 was demonstrated, and CO2 absorption lines relatively free of atmospheric water absorption interference at 6983 and 6984 cm-1 were experimentally observed, confirming feasibility of atmospheric CO2 sensing
A novel strategy to branched polyacrylonitrile via one-pot RAFT copolymerization of acrylonitrile and an asymmetrical divinyl monomer
Computer Aided Modeling of Polymer Reaction Engineering-The Status of Predici, I-Simulation
Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study
BACKGROUND AND AIMS: Despite advances in our knowledge of
effective services for people who use drugs over the last
decades globally, coverage remains poor in most countries, while
quality is often unknown. This paper aims to discuss the
historical development of successful epidemiological indicators
and to present a framework for extending them with additional
indicators of coverage and quality of harm reduction services,
for monitoring and evaluation at international, national or
subnational levels. The ultimate aim is to improve these
services in order to reduce health and social problems among
people who use drugs, such as human immunodeficiency virus (HIV)
and hepatitis C virus (HCV) infection, crime and legal problems,
overdose (death) and other morbidity and mortality. METHODS AND
RESULTS: The framework was developed collaboratively using
consensus methods involving nominal group meetings, review of
existing quality standards, repeated email commenting rounds and
qualitative analysis of opinions/experiences from a broad range
of professionals/experts, including members of civil society and
organisations representing people who use drugs. Twelve priority
candidate indicators are proposed for opioid agonist therapy
(OAT), needle and syringe programmes (NSP) and generic
cross-cutting aspects of harm reduction (and potentially other
drug) services. Under the specific OAT indicators, priority
indicators included 'coverage', 'waiting list time', 'dosage'
and 'availability in prisons'. For the specific NSP indicators,
the priority indicators included 'coverage', 'number of
needles/syringes distributed/collected', 'provision of other
drug use paraphernalia' and 'availability in prisons'. Among the
generic or cross-cutting indicators the priority indicators were
'infectious diseases counselling and care', 'take away
naloxone', 'information on safe use/sex' and 'condoms'. We
discuss conditions for the successful development of the
suggested indicators and constraints (e.g. funding, ideology).
We propose conducting a pilot study to test the feasibility and
applicability of the proposed indicators before their scaling up
and routine implementation, to evaluate their effectiveness in
comparing service coverage and quality across countries.
CONCLUSIONS: The establishment of an improved set of validated
and internationally agreed upon best practice indicators for
monitoring harm reduction service will provide a structural
basis for public health and epidemiological studies and support
evidence and human rights-based health policies, services and
interventions